November LIMR Clinical Research Report

By Donna Loyle, communications manager, LIMR


Research studies with clinical implications for patients with J Wave syndromes, brain metastases, periprosthetic joint infection and femoropopliteal artery lesions were published in peer-reviewed journals by investigators at the Lankenau Institute for Medical Research (LIMR) in November.


New therapeutic approach for J Wave syndromes

Experimental models showed that the natural flavone acacetin may be a promising new therapeutic to treat the life-threatening ventricular arrhythmias knows as the J Wave syndromes, which include Brugada and early repolarization syndromes. LIMR investigators: Charles Antzelevitch, PhD, distinguished professor emeritus, and LIMR research professors Jose Di Diego, MD; Hector Barajas-Martinez, PhD; and Alexander Burashnikov, PhD. The manuscript: “Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes” in PLoS One.


Tighter constraints recommended for HA-WBRT for brain metastases

A phase II clinical trial sought to determine if hippocampal avoidance during whole brain radiotherapy (HA-WBRT) for brain metastases can help to preserve patients’ cognitive function. Results showed a significant relationship between “maximum dose to the bilateral hippocampi and deterioration in short-term memory, even amongst patients who met hippocampal constraints according to the protocol, suggesting that tighter constraints may be beneficial.” LIMR investigator: Albert DeNittis, MD, clinical associate professor. The manuscript: “Steep Dose-response Relationship Between Maximum Hippocampal Dose and Memory Deficits Following Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: A Secondary Analysis of NRG/RTOG 0933” in International Journal of Radiation Oncology, Biology, Physics.


Diagnostic test for PJI showed promising results

In patient studies, the FDA-authorized alpha defensin lateral flow test to detect periprosthetic joint infection (PJI) showed sensitivity and specificity rates of 89.5% and 94.8%, respectively. The study also demonstrated the solid performance of the test to diagnose PJI in the clinic. The test was developed at LIMR by MLH orthopedic surgeon and LIMR clinical assistant professor Carl Deirmengian, MD. The manuscript: “Validation of the Alpha Defensin Lateral Flow Test for Periprosthetic Joint Infection” in The Journal of Bone & Joint Surgery.


Eluvia stent helped patients avoid lesion revascularization

The randomized IMPERIAL clinical trial, in which Main Line Health participated, sought to determine safety and patient outcomes of the Eluvia paclitaxel-eluting nitinol stent vs. the Zilver PTX paclitaxel-coated stent in patients with symptomatic femoropopliteal artery lesions. Two-year follow-up of the study’s patients showed a sustained advantage for Eluvia in avoiding target lesion revascularization. Other results showed no difference in prevalence between the study groups, no flow within the hypoechogenic halo, and no associated adverse events. The IMPERIAL study was an international, 65-site clinical trial that was led by LIMR clinical professor William Gray, MD, System Chief of the Division of Cardiovascular Diseases and Co-Director of the Lankenau Heart Institute. The manuscript: “Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent” in Cardiovascular and Interventional Radiology.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published.